Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Completed clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
121474
Shown on this page
12
Current sort
Recently updated
Status scope
Completed
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Completed. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 841–852 of 121,474 matching trials with status Completed.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

NCT07144111
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Inavolisib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Lake Forest, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Phase 3 Interventional

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

NCT06088199
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Not applicable Interventional

Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans

NCT04282395
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resilience-Based Diabetes Self-Management Education, Standard Diabetes Self-Management Education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Addition of Dehydrated Human Amnion-Chorion Membrane During Scaling and Root Planing

NCT03836378
View directory record Official record
Conditions
Periodontal Diseases
Interventions
BioXclude™
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Phase 3 Interventional Results available

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

NCT03362177
View directory record Official record
Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
Romiplostim, Placebo
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
22
States / cities
Jonesboro, Arkansas • Anaheim, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Social Media and Cancer Screening Information

NCT06712901
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Median Ranked Cancer Screening Messaging, Overall Preferred Cancer Screening Messaging, Black American Preferred Cancer Screening Messaging, White American Preferred Cancer Screening Messaging, Control
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
45 Years to 75 Years
Enrollment
2,030 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Skin Wetting in Burn Survivors

NCT06529757
View directory record Official record
Conditions
Burn Injury
Interventions
Whole body cooling, Non-cooling
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Phase 1 Interventional

Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy

NCT02362438
View directory record Official record
Conditions
Giant Axonal Neuropathy, Gene Transfer
Interventions
scAAv9/JeT-GAN
Genetic
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
3 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed No phase listed Observational Results available

MOms in REcovery (MORE) Study: Defining Optimal Care

NCT04251208
View directory record Official record
Conditions
Opioid-Related Disorders, NAS, Substance Use Disorders, Mental Health
Interventions
Observational Study
Other
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
2,510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Augusta, Maine • Bangor, Maine • Keene, New Hampshire + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Phase 1 Interventional

Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

NCT00720135
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
Interventions
DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, enzyme-linked immunosorbent assay, reverse transcriptase-polymerase chain reaction
Biological · Other · Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Phase 2 Interventional Results available

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

NCT02505269
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Adriamycin, Dacarbazine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Don't Throw Your Heart Away: Patient Study 4

NCT04809051
View directory record Official record
Conditions
Cardiac Transplant Disorder
Interventions
Stratified Transplant Survival Metric, SRTR Information Format
Other
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 6, 2026, 5:10 PM EST